ES2074006A1 - Glicosidos esteroidales para tratar hipercolesterolemia. - Google Patents

Glicosidos esteroidales para tratar hipercolesterolemia.

Info

Publication number
ES2074006A1
ES2074006A1 ES09301507A ES9301507A ES2074006A1 ES 2074006 A1 ES2074006 A1 ES 2074006A1 ES 09301507 A ES09301507 A ES 09301507A ES 9301507 A ES9301507 A ES 9301507A ES 2074006 A1 ES2074006 A1 ES 2074006A1
Authority
ES
Spain
Prior art keywords
steroid glycosides
hypercholesterolaemia
treating
treating hypercholesterolaemia
glycosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09301507A
Other languages
English (en)
Other versions
ES2074006B1 (es
Inventor
Michael Paul Deninno
Carthy Peter Andrew Mc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to ES9301507A priority Critical patent/ES2074006B1/es
Publication of ES2074006A1 publication Critical patent/ES2074006A1/es
Application granted granted Critical
Publication of ES2074006B1 publication Critical patent/ES2074006B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Steroid Compounds (AREA)

Abstract

GLICOSIDOS ESTEROIDALES PARA TRATAR HIPERCOLESTEROLEMIA. LA INVENCION SE REFIERE A GLICOSIDOS ESTEROIDALES DE FORMULA IA EN LA QUE Q1, Q2, Q3, Q4 Y Q5 SON GRUPOS METILENO O CARBONILO O PUEDEN CONTENER UN GRUPO HIDROXILO OPCIONALMENTE SUSTITUIDO, C5 ES AL Y C25 ES (R). LOS COMPUESTOS SON ADECUADOS PARA EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA O ARTEROESCLEROSIS EN UN MAMIFERO.
ES9301507A 1993-07-05 1993-07-05 Glicosidos esteroidales para tratar hipercolesterolemia. Expired - Fee Related ES2074006B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9301507A ES2074006B1 (es) 1993-07-05 1993-07-05 Glicosidos esteroidales para tratar hipercolesterolemia.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9301507A ES2074006B1 (es) 1993-07-05 1993-07-05 Glicosidos esteroidales para tratar hipercolesterolemia.

Publications (2)

Publication Number Publication Date
ES2074006A1 true ES2074006A1 (es) 1995-08-16
ES2074006B1 ES2074006B1 (es) 1996-03-16

Family

ID=8282450

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9301507A Expired - Fee Related ES2074006B1 (es) 1993-07-05 1993-07-05 Glicosidos esteroidales para tratar hipercolesterolemia.

Country Status (1)

Country Link
ES (1) ES2074006B1 (es)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159431A2 (en) * 1984-04-20 1985-10-30 Medical Research Foundation Of Oregon Tigogenin-cellobioside and its heptaacetate, methods for their preparation, and pharmaceutical compositions containing tigogenin-cellobioside
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
EP0403150A2 (en) * 1989-06-13 1990-12-19 Pfizer Inc. Process for the preparation of tigogenin beta-cellobioside
WO1993007167A1 (en) * 1991-10-04 1993-04-15 The Procter & Gamble Company Cholesterol lowering compounds and process for making them
WO1994000480A1 (en) * 1992-06-26 1994-01-06 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
WO1994025479A1 (en) * 1993-04-28 1994-11-10 Pfizer Inc. Spirostanyl glycosidal crystalline monohydrate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
EP0159431A2 (en) * 1984-04-20 1985-10-30 Medical Research Foundation Of Oregon Tigogenin-cellobioside and its heptaacetate, methods for their preparation, and pharmaceutical compositions containing tigogenin-cellobioside
EP0403150A2 (en) * 1989-06-13 1990-12-19 Pfizer Inc. Process for the preparation of tigogenin beta-cellobioside
WO1993007167A1 (en) * 1991-10-04 1993-04-15 The Procter & Gamble Company Cholesterol lowering compounds and process for making them
WO1994000480A1 (en) * 1992-06-26 1994-01-06 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
WO1994025479A1 (en) * 1993-04-28 1994-11-10 Pfizer Inc. Spirostanyl glycosidal crystalline monohydrate

Also Published As

Publication number Publication date
ES2074006B1 (es) 1996-03-16

Similar Documents

Publication Publication Date Title
SI0680963T1 (en) (Hydroxyphenylamino)carbonyl pyrroles
EP0626174A3 (en) Method and composition for the prophylaxis and / or treatment of underactive organs.
PL328858A1 (en) Immunogenous peptides
GR3023233T3 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
UA70956C2 (uk) Інгібітори стероїдсульфатази
MXPA01005545A (es) Composicion y metodo para tratamiento de cancer que usan moduladores de transduccion de senales y aceites esenciales vegetales naturales.
EP0693928A4 (en) COMPOSITION BASED ON AMINO SUGARS AND GLYCOSAMINOGLYCANS FOR THE TREATMENT AND REPAIR OF CONNECTIVE TISSUE
ZA943744B (en) Therapeutic substituted guanidines
UA35589C2 (uk) ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
EP0654992A4 (en) METHOD FOR TREATING AND PREVENTING IRRITABLE COLON SYNDROME AND PHARMACEUTICAL COMPOSITIONS USED THEREFOR.
AU4028995A (en) Antitumor compositions and methods of treatment
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU8044491A (en) Antitumor compositions and methods of treatment
AU2209500A (en) Inhibitors of alpha4beta1 mediated cell adhesion
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
NO974320L (no) Fucopeptider
ATE283044T1 (de) Compactin zur behandlung von entzündungen
BR9710957A (pt) Composição compreendendo um inibidor de canal katp uso no tratamento hemorrágico
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
AU7669391A (en) Novel cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis
EP2256202A3 (en) Stimulus-inducible i (kappa)b kinase ikk signalsome
ES2074006A1 (es) Glicosidos esteroidales para tratar hipercolesterolemia.
CA2226140A1 (en) Compounds for treating or preventing osteoporosis and symptoms associated with menopause
MY100890A (en) 5(alpha) - reductase inhibitor.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20040503